Acute decompensated chronic heart failure

Article written and reviewed by Dr Luca Moretti

Acute decompensated chronic heart failure is clinically relevant worsening of an already known syndrome, characterized by new or increasing congestion, hypoperfusion, or both, and severe enough to require treatment intensification. It may be managed in an outpatient clinic, day hospital, emergency department, or during hospitalization: a need for intravenous diuretics is not essential to the definition, because even a substantial increase in oral therapy represents a worsening heart failure event with prognostic significance. Acute decompensation is not a disease separate from chronic heart failure, but a transition in state. The patient reaches the event through a trajectory that may include a progressive increase in total body sodium, rapid venous redistribution, worsening cardiac function, loss of adherence, infection, ischemia, arrhythmia, or renal deterioration; multiple mechanisms often contribute, and in a substantial proportion no single precipitant emerges. Every episode should be considered a diagnostic and therapeutic opportunity. Merely removing edema without identifying the cause, phenotype, and incomplete therapy exposes the patient to recurrence; effective discharge requires decongestion, stability, transition to oral therapy, introduction of prognosis-modifying treatments, and close follow-up.

Risk does not end with symptom improvement. The first weeks after hospitalization constitute a vulnerable phase in which neurohormonal activation, renal abnormalities, subclinical congestion, medication changes, and frailty persist; death and rehospitalization are concentrated in this period. The clinical profile must distinguish congestion from hypoperfusion and define blood pressure, rhythm, right and left ventricular function, valves, ischemia, and organ damage. “Warm-wet,” “cold-wet,” “cold-dry,” and “warm-dry” are useful frameworks to guide the approach, but do not replace serial measurements and reassessments. Management is dynamic: diuretic response, blood pressure, urine output, urinary sodium, creatinine, electrolytes, oxygenation, and perfusion must be checked early. Inertia in the first hours prolongs exposure to congestion; excessively aggressive treatment without monitoring can instead produce hypovolemia, hypotension, and injury.

Etiology, pathogenesis, and pathophysiology

The event may result from progression of the underlying heart disease or from a reversible factor. Myocardial ischemia and acute coronary syndrome reduce contractility, impair relaxation, and induce mitral regurgitation or arrhythmias; pain may be absent in people with diabetes, older adults, and patients with previous infarction, making ECG and troponin interpreted in context essential. Rapid atrial fibrillation reduces filling time and atrial contraction, while bradycardia and conduction blocks reduce cardiac output; ventricular tachycardias or a high ectopic beat burden can cause arrhythmia-induced cardiomyopathy. The arrhythmia may be a cause or consequence of congestion, and correcting it does not eliminate the need for decongestion. A hypertensive crisis and an abrupt increase in afterload raise pulmonary pressures within minutes, particularly in stiff ventricles. Pulmonary edema may therefore reflect blood redistribution more than major total retention, with nearly unchanged weight and very high blood pressure.

Respiratory, urinary, or systemic infections increase demand, heart rate, and vascular permeability and may depress the myocardium. Fever may be absent in older adults; sepsis may simultaneously produce vasodilation, cardiac dysfunction, and a need for fluids, requiring a strategy different from simple diuretic intensification. Acute or chronic anemia, thyrotoxicosis, severe hypothyroidism, pulmonary embolism, COPD exacerbation, and respiratory failure increase cardiac load or mimic acute decompensation. The diagnosis must not be attributed to heart failure solely because BNP is elevated in a patient with heart disease. Acute aortic or mitral regurgitation, endocarditis, prosthetic valve thrombosis, chordal rupture, prosthetic valve dysfunction, and severe tricuspid regurgitation are mechanical precipitants; a new murmur, hemolysis, sudden pulmonary edema, or instability requires urgent imaging and interventional assessment.

Nonsteroidal anti-inflammatory drugs, corticosteroids, thiazolidinediones, some calcium channel blockers, and cancer therapies may promote retention, hypertension, or myocardial dysfunction. Withdrawal of diuretics or prognosis-modifying drugs, prescribing errors, and nonadherence may result from costs, adverse effects, poor understanding, cognitive impairment, or depression and should not be reduced to blaming the patient. Excess sodium or fluid may contribute, but rarely explains severe events on its own in well-compensated disease. Vomiting, diarrhea, and heat may instead produce hypovolemia, kidney failure, and reduced drug elimination, with a “cold-dry” profile that does not benefit from further diuresis. Progression of kidney disease, urinary obstruction, and drug interactions alter natriuresis and potassium; a rise in creatinine may precede, accompany, or follow worsening and requires a distinction among venous congestion, low perfusion, nephrotoxicity, and intrinsic injury.

Sodium retention often begins before symptoms through increased proximal and distal reabsorption, renin-angiotensin-aldosterone activation, and reduced perfusion pressure. The braking phenomenon and tubular hypertrophy reduce the effect of chronic diuretics; intestinal absorption of the oral drug becomes variable with bowel wall edema; congestion is not synonymous with hypervolemia. Splanchnic venoconstriction reduces capacitance and shifts blood to the thorax; a patient may have severe dyspnea with little change in total volume, or massive edema with relatively well-tolerated pulmonary pressures. The phenotype determines the relative importance of vasodilators and diuretics; increased central venous pressure reduces the transrenal gradient, causes interstitial edema, and worsens the natriuretic response. This renal congestion explains why further fluid removal can improve function in some patients despite an initial rise in creatinine.

Low cardiac output activates sympathetic and hormonal vasoconstriction, preserving blood pressure at the expense of peripheral perfusion. Occult hypoperfusion may present with apparently normal blood pressure but cold extremities, oliguria, confusion, or rising lactate; a blood pressure threshold alone does not define shock. The right ventricle is particularly vulnerable to embolism, pulmonary hypertension, positive-pressure ventilation, and volume overload. Dilation shifts the septum, reduces left heart filling, and increases venous pressure; treatment that excessively reduces preload may worsen cardiac output in preload-dependent right-sided forms. Inflammation, oxidative stress, subendocardial ischemia, and neurohormonal activation produce organ damage. Elevated troponin in heart failure does not automatically demonstrate a primary myocardial infarction, but identifies myocardial injury and risk and requires investigation of the mechanism.

Diuretic resistance results from an inadequate dose, reduced delivery to the tubule, hypoalbuminemia, kidney failure, distal adaptation, high sodium intake, and poor perfusion. The early natriuretic response is more informative than urine output alone, which may contain free water without adequate sodium removal. Hypochloremia and metabolic alkalosis accompany prolonged diuresis and may increase reabsorption; acetazolamide acts on the proximal tubule and, in the ADVOR trial, increased successful decongestion in patients with overload. Its effectiveness does not eliminate the need for selection and acid-base monitoring. Ultrafiltration removes sodium and water in a controllable manner, but CARRESS-HF showed worse renal outcomes than a stepped pharmacological strategy in patients with cardiorenal syndrome. Its role remains in selected refractory cases, not as a routine early alternative.

Clinical manifestations

Typical worsening includes increased dyspnea, orthopnea, nocturnal awakenings, reduced exercise tolerance, edema, and weight gain. Symptoms may progress over days or appear within hours; the speed points toward gradual retention, redistribution, an ischemic event, arrhythmia, or a mechanical lesion. Abdominal distention, nausea, early satiety, and right upper quadrant pain indicate splanchnic and hepatic congestion. Reduced appetite and tissue loss may conceal fluid accumulation, making weight falsely reassuring. Fatigability, drowsiness, confusion, oliguria, and cold extremities suggest reduced cardiac output; a presentation without crackles does not exclude elevated filling pressure, particularly in chronic heart failure with lymphatic adaptation.

The “warm-wet” profile is the most frequent and combines congestion with preserved perfusion; “cold-wet” identifies congestion and hypoperfusion and carries greater risk. “Cold-dry” may represent hypovolemia or low reserve without obvious congestion, while “warm-dry” describes relative compensation. Blood pressure is a therapeutic discriminator. High values suggest reserve for vasodilation and often redistribution; persistent hypotension may reflect low cardiac output, sepsis, arrhythmia, or excessive drug effects; the patient’s usual blood pressure is more informative than an isolated threshold. Tachycardia, an irregular pulse, bradycardia, reduced oxygen saturation, fever, and tachypnea help identify precipitants; respiratory rate is an early indicator of severity, often more sensitive than subjective perception.

Jugular venous pressure and hepatojugular reflux are central signs of venous congestion. Edema, ascites, hepatomegaly, and effusions confirm the picture, but obesity limits examination and venous insufficiency confounds edema assessment; a multimodal evaluation reduces error. Crackles, ultrasound B-lines, and effusions indicate lung water, but may result from interstitial lung disease or infections; a new murmur, third heart sound, displaced apex beat, or accentuated pulmonary component of the second heart sound points toward valvular disease, overload, or pulmonary hypertension. Signs of severity include dyspnea at rest, accessory muscle use, cyanosis, altered mental status, ischemic pain, syncope, oliguria, elevated lactate, and shock. These findings require intensive monitoring and an immediate search for the reversible cause.

Acute decompensation of right-sided heart failure may present with edema, ascites, and hepatic congestion but clear lungs. Severe tricuspid regurgitation produces prominent v waves, hepatic pulsations, and low cardiac output; invasive ventilation may aggravate right ventricular afterload and requires planning. In older patients, delirium, falls, poor appetite, and functional decline sometimes predominate over dyspnea. Frailty, cognitive impairment, and polypharmacy increase the risk of atypical presentations and iatrogenic complications; outpatient worsening may be subtler: an increased diuretic dose, reduced walking distance, new orthopnea, or an increase in peptides. Recognizing outpatient worsening allows early intervention and does not diminish its prognostic significance.

Investigations and diagnosis

The initial assessment pursues stabilization and diagnosis simultaneously. Airway, breathing, circulation, mental status, oxygen saturation, blood pressure, and perfusion identify urgency; a targeted history reconstructs the chronology, weight, diuretics, adherence, pain, fever, palpitations, and medications. An ECG within minutes looks for ischemia, arrhythmias, conduction blocks, and signs of overload. High-sensitivity troponin is recommended, but a dynamic elevation must be interpreted with symptoms, ECG, and imaging to distinguish primary or secondary myocardial infarction, acute nonischemic myocardial injury, and chronic myocardial injury. A complete blood count, creatinine, blood urea nitrogen, sodium, potassium, chloride, bicarbonate, glucose, liver function tests, and urinalysis define precipitants and injury. Blood gas analysis and lactate are indicated in respiratory distress, hypoperfusion, or shock, not necessarily in every stable patient.

Low BNP or NT-proBNP makes acute heart failure unlikely in the appropriate context; elevated values are nonspecific and are influenced by age, atrial fibrillation, kidney function, embolism, and obesity. Comparison with baseline increases their value, but the clinical diagnosis must not be replaced by a threshold. Chest radiography identifies congestion, edema, effusions, cardiomegaly, and alternatives such as pneumonia or pneumothorax; a normal radiograph does not exclude elevated pressures, especially in early stages or right-sided heart failure. Lung ultrasound detects B-lines and effusions with greater sensitivity and tracks the response; venous and organ ultrasound may describe systemic congestion; findings depend on technique and interstitial diseases and must be integrated.

Urgent echocardiography is essential in instability, a new murmur, a suspected mechanical complication, shock, or diagnostic uncertainty. It assesses ventricular function, valves, the pericardium, stroke volume, and pulmonary pressure; the ejection fraction during the event is affected by loading conditions and must not erase the history. Bedside assessment of the outflow tract, right ventricle, and pericardium can guide fluids, vasodilators, and inotropes. The vena cava alone does not accurately measure blood volume during ventilation, tricuspid regurgitation, or elevated abdominal pressure. CT angiography, coronary angiography, transesophageal echocardiography, or magnetic resonance imaging are selected to investigate embolism, the aorta, coronary arteries, valves, myocarditis, or other causes; advanced tests must not delay lifesaving treatment.

The diuretic response should be measured early using hourly urine output, fluid balance, and, when available, urinary sodium after the bolus; an insufficient response in the first hours requires a dose increase or combination therapy, not passive waiting until the following day. Daily weight is useful but influenced by scales, food intake, and insensible losses; fluid balance may be inaccurate; examination, symptoms, jugular veins, ultrasound, kidney function, and blood concentration measures must converge to define decongestion. An increase in hematocrit or albumin may suggest hemoconcentration, but is not an isolated target. Residual congestion matters more than a moderate change in creatinine if blood pressure and urine output remain adequate.

Right heart catheterization is not routine, but is indicated in shock, refractory hypoperfusion, discordant findings, suspected pulmonary hypertension, or failure to respond. Pulmonary capillary wedge pressure, right atrial pressure, cardiac output, and vascular resistance clarify the profile; incorrect zeroing, wedge measurements, or oxygen consumption measurements produce dangerous decisions. Urgent coronary angiography is guided by acute coronary syndrome, electrical or mechanical instability, and the likelihood of benefit. Elevated troponin without evidence of occlusion does not automatically justify an emergency invasive strategy. Cultures, CRP, procalcitonin, TSH, D-dimer, and infection testing are selective; diagnosing the precipitant must avoid indiscriminate panels as well as anchoring on previously known heart failure.

Before discharge, etiology, weight, blood pressure, rhythm, function, congestion, creatinine, electrolytes, iron status, and treatment must be documented; reconciliation identifies temporarily discontinued drugs and establishes when to reintroduce them; a generic “follow up with the treating physician” is not a sufficient plan. Stability criteria include improvement in the cause, no need for intravenous therapy, effectiveness of the oral regimen, adequate oxygenation and perfusion, ambulation, and support. Perfect euvolemia may not be achievable, but residual congestion must be explicitly documented and managed; the risk of readmission increases with previous hospitalizations, kidney disease, hyponatremia, hypotension, frailty, and social barriers. Scores do not replace multidimensional assessment or scheduling a review within days.

Treatment and prognosis

Oxygen is indicated in hypoxemia, not routinely when oxygen saturation is normal. Noninvasive ventilation reduces the work of breathing and the need for intubation in pulmonary edema, provided the patient can protect the airway and does not have shock; invasive ventilation requires attention to the fall in venous return and to the right ventricle. Intravenous loop diuretics are the central treatment for congestion. The initial dose must consider chronic exposure and kidney function; DOSE showed that a high-dose strategy produces greater relief and diuresis with more transient changes in creatinine, without a substantial difference between bolus and continuous infusion. The response is reassessed in the first hours. If insufficient, the effective dose is rapidly doubled, frequency is increased, or a diuretic acting on another segment is added, while maintaining monitoring of electrolytes, blood pressure, and kidney function.

Acetazolamide added to a loop diuretic increases the probability of decongestion in patients with overload, as in ADVOR; thiazides or metolazone block the distal nephron and are useful in resistance. The combination may cause hyponatremia, hypokalemia, alkalosis, or renal deterioration and is not automatic; nitrate vasodilators reduce preload and afterload when blood pressure is adequate, particularly in hypertensive pulmonary edema. They have not demonstrated a routine prognostic benefit and are contraindicated in hypotension, recent use of PDE5 inhibitors, and some preload-dependent conditions. Opioids should not be used routinely for acute dyspnea because of the risk of respiratory depression and unfavorable associations. Tolvaptan corrects excess free water and hyponatremia in selected patients, but EVEREST did not demonstrate a reduction in long-term mortality.

Inotropes such as dobutamine or milrinone are reserved for hypoperfusion with low cardiac output and inadequate blood pressure, as a bridge to recovery, decision, mechanical support, or palliation. They increase arrhythmias and oxygen consumption; the choice depends on blood pressure, beta-blockade, kidney function, and pulmonary vascular resistance; norepinephrine is generally the initial vasopressor in cardiogenic shock with hypotension, titrated to the minimum required for perfusion. Raising blood pressure does not guarantee cardiac output and may aggravate afterload; lactate, urine output, and mental status guide the response. Temporary mechanical support requires selection according to etiology, the ventricle involved, potential for recovery, and goals. Routine use of early ECLS in post-infarction shock did not improve survival in ECLS-SHOCK and increased complications, underscoring the need for phenotyping.

The precipitant must be treated concurrently: revascularization in appropriate cases of myocardial infarction, cardioversion in arrhythmic instability, antibiotics for infection, intervention for a mechanical lesion, anticoagulation for embolism, and endocrine or hematological correction. Decongestion alone does not resolve a persistent cause. Chronic prognosis-modifying drugs should not be automatically discontinued. Beta-blockers are maintained if perfusion and blood pressure permit; RAASi/ARNI and MRA may require temporary withholding in shock, hyperkalemia, or severe kidney injury, but should be reintroduced as soon as possible. SGLT2 inhibitors can be started in hospital after stabilization; EMPULSE supported an early clinical benefit independent of ejection fraction. Assessment of eGFR, ketoacidosis, fasting, and infections and a plan for the sick-day rule are needed.

In HFrEF, ARNI or RAASi, a beta-blocker, MRA, and an SGLT2 inhibitor should be started or optimized before discharge whenever possible. PIONEER-HF demonstrated the feasibility of sacubitril/valsartan after stabilization; hospitalization is an opportunity to overcome inertia, not a reason to postpone everything. STRONG-HF showed that a high-intensity care pathway with rapid titration and early visits reduces death or readmission in selected, stabilized patients. This does not mean indiscriminately increasing every dose: blood pressure, heart rate, potassium, kidney function, and congestion define the sequence. In patients with an ejection fraction of at least 40%, SGLT2 inhibitors are fundamental; finerenone may reduce events according to FINEARTS-HF. Obesity, atrial fibrillation, hypertension, and specific phenotypes must be addressed after stabilization.

Intravenous iron in patients with deficiency after hospitalization may reduce heart failure events and improve functional status, although studies differ in formulation and endpoints. Diagnosis uses ferritin and transferrin saturation; hemoglobin alone does not identify iron deficiency. Thromboprophylaxis is indicated in immobilized hospitalized patients who are not receiving anticoagulation and have an acceptable bleeding risk. Nutrition, early mobilization, delirium prevention, and physical therapy reduce iatrogenic decline; discharge requires a reference weight, an observed oral dose, instructions on signs, creatinine and potassium checks, an appointment, and contact details. Follow-up within one week, earlier in frail patients, allows correction of recurrent congestion and titration.

Prognosis depends on event severity, cause, response, right heart function, kidney function, sodium, blood pressure, troponin, peptides, and frailty. Worsening treated outside the hospital is not benign; recurrent events identify a trajectory toward advanced disease; hospitalizations must trigger assessment for advanced therapies when a need for inotropes, hypotension, refractory congestion, organ dysfunction, or drug intolerance appears. Waiting for irreversible shock reduces eligibility for transplantation or mechanical support. When therapies targeting the cause and advanced options are not appropriate, palliative care and advance care planning improve symptom control and alignment of care; preferences regarding further hospitalizations, resuscitation, and devices should be discussed outside a crisis whenever possible.

Complications

Acute kidney injury during decompensation may result from congestion, low perfusion, sepsis, nephrotoxic agents, or excessive fluid removal. Cardiorenal syndrome requires interpretation: a moderate rise in creatinine with natriuresis and clinical improvement differs from oliguria, hypotension, and abnormal urinary sediment. Hyponatremia due to excess free water signals elevated vasopressin and severe disease; hypokalemia and hypomagnesemia increase arrhythmias, while hyperkalemia limits RAASi use; rapid sodium correction exposes the patient to neurological injury and must adhere to safe rates. Hepatic congestion and hypoxic hepatitis alter bilirubin, INR, and aminotransferases; splanchnic hypoperfusion promotes ileus, intestinal ischemia, and malabsorption, especially in shock.

Pulmonary edema, respiratory failure, and the need for ventilation may be complicated by pneumonia, barotrauma, and acquired weakness; positive-pressure ventilation reduces left-sided congestion but may decrease venous return and worsen right heart function. Atrial fibrillation, ventricular tachycardia, bradycardia, and cardiac arrest require correction of ischemia, oxygenation, and electrolytes. Sudden death may occur even after stabilization; ICD indications are reassessed after optimal therapy and an appropriate interval, avoiding automatic implantation during potentially reversible dysfunction. Venous thromboembolism and stroke increase with immobility and atrial fibrillation. Anticoagulation must balance kidney function, liver function, procedures, and bleeding, without using heart failure alone as an indication.

Iatrogenic hypotension may result from the combined effects of diuretics, vasodilators, sedatives, and ventilation. Management requires identifying the contribution of volume, cardiac output, and vasoplegia; an indiscriminate fluid bolus in a congested patient may aggravate edema and right heart function. Prolonged diuretic resistance exposes the patient to pharmacological escalation, repeated presentations, and electrolyte abnormalities. Before labeling the condition refractory, dose, absorption, sodium, interfering drugs, intra-abdominal pressure, and kidney function must be checked. Ultrafiltration, inotropes, and mechanical support cause bleeding, infectious, vascular, and renal complications. Every escalation must have a defined goal and stopping criteria.

Delirium, falls, immobility, pressure injuries, and muscle loss are frequent in older adults. Hospital-associated frailty may turn an event that has resolved hemodynamically into permanent loss of independence; mobilization, sleep, sensory aids, and nutrition are clinical interventions, not optional extras. Transition errors, duplication, failure to reintroduce medications, and lack of follow-up cause preventable events; the discharge document must explain changes, reasons, and monitoring, coordinating the cardiologist, primary care, and community services. Depression, anxiety, and fear of dyspnea may reduce adherence and activity; caregiver support and a written action plan improve the ability to recognize and manage worsening early.

Repeated acute decompensations accelerate multiorgan damage, sarcopenia, and cachexia and may indicate advanced heart failure. Increasing diuretic doses, multiple hospitalizations in one year, hypotension, hyponatremia, right heart dysfunction, and treatment intolerance are signs for specialist referral; the absence of an obvious precipitant may reflect the natural progression of heart disease or unrecognized congestion. In such cases, ischemia, valves, amyloidosis, arrhythmias, devices, and adherence should be reconsidered before concluding that no modifiable cause exists. The most important complication is an incomplete discharge: improved symptoms but residual fluid, unoptimized therapy, and no follow-up; prevention of the next acute decompensation begins during the episode, not at the next visit.